Spelling suggestions: "subject:"costs anda cost analysis"" "subject:"costs ando cost analysis""
101 |
Estudos para avaliação de custo-efetividade do tratamento do transtorno de déficit de atenção/hiperatividade com metilfenidato de liberação imediata no BrasilMaia, Carlos Renato Moreira January 2014 (has links)
Introdução O Transtorno de Déficit de Atenção/hiperatividade (TDAH) tem sido muito estudado, mas informações econômicas referentes ao seu tratamento com o metilfenidato de liberação imediata (MFD-LI) ainda necessitam ser exploradas. Grande parte da população mundial, principalmente aqueles que vivem em países em desenvolvimento, utiliza essa formulação como principal escolha para o tratamento do TDAH. Esses países, por sua condição financeira, necessitam informações de análises econômicas para administrar de forma eficiente os recursos públicos destinados aos setores da saúde. Objetivos Avaliar a eficácia do MFD-LI através de estudos com tempo superior a 12 semanas, e realizar uma análise econômica para o tratamento do TDAH com MFD-LI para crianças e adolescentes brasileiros. Método O estudo foi planejado em cinco etapas: 1) estimativa de custo do não tratamento do TDAH para o Brasil, e estimativa de economia com tratamento com MFD-LI; 2) revisão sistemática da literatura nas principais bases de dados internacionais onde se buscaram estudos abertos com tratamento do TDAH com MFD-LI por tempo igual ou superior a 12 semanas; também foram feitas metanálises e uma metaregressão 3) estudo naturalístico para obterem-se dados de uma amostra brasileira referentes a probabilidades de uso e sucesso com tratamento com MFD-LI por 12 semanas, e estimar os utilities desses indivíduos; 4) painel Delphi com especialistas em TDAH no Brasil; 5) estudo de custo-efetividade para o tratamento do TDAH com MFD-LI no Brasil, utilizando um Modelo de Markov. A perspectiva adotada será a do sistema público de saúde brasileiro como pagador. Resultados Os resultados principais encontrados para cada uma das etapas foram: 1) a estimativa de custos anuais com o TDAH não tratado no Brasil foi de R$ 1.594 bilhões/ano, e da quantia que poderia ser economizada se tratado, R$ 1 bilhão/ano. 2) na revisão sistemática da literatura, de 4.498 resumos, sete foram incluídos para compor a metanálise. O tempo de tratamento variou entre 13 e 104 semanas. O efeito agregado para desatenção e hiperatividade medida pelos pais, respectivamente, foi 0.96 (95%CI 0.60 - 1.32) e 1.12 (95%CI 0.85 - 1.39), e pelos professores 0.98 (95%CI 0.09 - 1.86) e 1.25 (95% CI 0.7 - 1.81). A metaregressão não mostrou associação entre as variáveis idade, qualidade do artigo e tempo de tratamento com heterogeneidade. 3) no estudo naturalístico, de 171 pacientes avaliados, 73 forneceram informações para o baseline, e 56 para a 12a semana de tratamento com MFD-LI. Os utilities para um paciente com TDAH não tratado (baseline) foram 0.69 (crianças) e 0.66 (adolescentes), e estimaram-se ganhos entre 0.09 a 0.10 utilities/mês, se tratados adequadamente. 4) no painel Delphi, de 26 especialistas, 14 responderam o questionário online, e foi estimado que a probabilidade dos pacientes não tratados se manterem sintomáticos na 12a semana seria de 91%, e 9% a probabilidade de melhora espontânea; 5) no estudo de custo-efetividade, para o caso base, estimou-se que o Incremental Cost Effectiveness Ratio (ICER) seja I$9,103/QALY (Quality Adjusted Life Years) para crianças e I$11,883/QALY para adolescentes em um horizonte temporal de 06 anos. Para os cenários mais desfavoráveis, os ICERS mais elevados foram I$95,164/QALY para 50% de sucesso com o tratamento, e I$15,000/QALY para 70% de adesão em um horizonte temporal de 06 anos. Conclusões O MFD-LI é um tratamento eficaz para crianças e adolescentes, por um período superior a 12 semanas. Entretanto, o Brasil pode estar aumentando os custos referentes à saúde por não estar fornecendo um tratamento eficaz e economicamente acessível para o TDAH. O tratamento mostrou ser uma opção custo-efetiva para crianças e adolescentes brasileiros, mesmo em cenários desfavoráveis para o tratamento. / Introduction Attention-Deficit/Hyperactivity Disorder (ADHD) is a well-known psychiatric disorder, but some economical aspects of the treatment with Methylphenidate Immediate-release (MPH -IR) still need to be explored. A large number of people around the world, most living in Low-Middle Income Countries (LMIC), use this formulation as the first choice for ADHD treatment. These countries, due to their financial condition, need information from health economic analyzes to efficiently manage the public resources allocated to the health sector. Objective To study the efficacy of MPH-IR reviewing studies conducted for more than 12 weeks long, and to perform an economic analysis for the treatment of ADHD with MPH-IR for Brazilian children. Method The study was planned in a five stages process: 1) to estimate the cost of untreated ADHD for Brazil, and to estimate the savings if MPH-IR were adequately provided; 2) systematic review of the literature to identify papers published where young patients with ADHD were treated with MPH-IR for more than 12 weeks, and to perform a meta-analysis and a meta-regression; 3) to conduct a naturalistic study with a Brazilian sample to collect the probabilities of use and success with the MPH-IR treatment for 12 weeks, and to estimate the utilities; 4) to perform a Delphi panel with ADHD Brazilian experts; 5) to conduct a cost-effectiveness analysis for the treatment of ADHD with MPH-IR in Brazil, using a Markov model. The perspective is the one of the Brazilian public health system as the payer. Results The main findings for each step were: 1) the estimated annual expenditures with untreated ADHD in Brazil were R$1.594billon/year, and the estimated amount that could be saved was R$1billion/year; 2) in the systematic review, from 4,498 abstracts, 7 studies were selected. The length of treatment ranged from 13 to 104 weeks. The aggregate effects for inattention and hyperactivity, according to parents evaluations were respectively 0.96 (95%CI 0.60 - 1.32) and 1.12 (95%CI 0.85 - 1.39), and for teachers 0.98 (95%CI 0.09 - 1.86) e 1.25 (95% CI 0.7 - 1.81). There was no evidence of association between heterogeneity and the variables, age, paper quality and length of treatment; 3) in the naturalistic study, from 171 patients assessed, 73 provided information in the baseline, and 56 in the 12th week of MPH-IR treatment. Utilities for an untreated ADHD patient (baseline) were 0.69 (children) and 0.66 (adolescents), and it was estimated a gain ranging from 0.09 to 0.10 utilities/month if subjects were properly treated; 4) in the Delphi Panel, 26 experts were addressed and 14 filled in the online questionnaire. It was estimated the probability of untreated patients to remain symptomatic on the 12th week to be 91%, and the probability of spontaneous improvement, 9%; 5) in the cost-effectiveness analysis, for the base case, it was estimated an Incremental Cost Effectiveness Ratio (ICER) of I$9,103/QALY (Quality Adjusted Life Years) for children and I$11,883/QALY for adolescents, in a time horizon of 6 years. The worst case scenarios were also tested, and the highest ICER were I$95,164/QALY when patient reached 50 % of success with the treatment, and I$15,000/QALY if only 70% of use was observed in a time horizon of 6 years. Conclusions MPH-IR is an efficacious treatment for ADHD children and adolescents for periods longer than 12 weeks. However, Brazil may be probably wasting money due to not provide an efficient and affordable treatment for ADHD such as the MPH-IR. The treatment proved to be cost-effective for children and adolescents living in Brazil, even when the worst case scenarios were tested.
|
102 |
Custo do teste Anti-HBs pós-vacinação primária em relação ao manejo para hepatite B pós-exposição à material biológico entre trabalhadores da área da saúde / The cost of primary post-vaccination Anti-HBs testing in relation to hepatitis B post-exposure practices among health care workersSouza, Camila Lucas de 11 May 2018 (has links)
Submitted by Franciele Moreira (francielemoreyra@gmail.com) on 2018-07-09T12:16:28Z
No. of bitstreams: 2
Dissertação - Camila Lucas de Souza - 2018.pdf: 2326676 bytes, checksum: 8ce05f9e4402bf801ab775da922be861 (MD5)
license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2018-07-10T10:59:46Z (GMT) No. of bitstreams: 2
Dissertação - Camila Lucas de Souza - 2018.pdf: 2326676 bytes, checksum: 8ce05f9e4402bf801ab775da922be861 (MD5)
license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2018-07-10T10:59:46Z (GMT). No. of bitstreams: 2
Dissertação - Camila Lucas de Souza - 2018.pdf: 2326676 bytes, checksum: 8ce05f9e4402bf801ab775da922be861 (MD5)
license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Previous issue date: 2018-05-11 / INTRODUCTION: Hepatitis B virus (HBV) infection is a worldwide public health problem and
the cost of treatment for hepatitis B is high. Work related accidents with biological material
among health care workers present a risk of transmission of this virus. The primary preventive
measure against HBV is vaccination, followed by an anti-HBs test one to two months after the
final dose of the vaccine, however this test is not part of the pre-exposure routine in Brazilian
public health. OBJECTIVES: To compare the direct medical cost, from the public health
perspective, of the evaluation of pre-exposure serological status vs the post-exposure
management of hepatitis B virus-related occupational exposure among exposed health care
workers. The specific objectives were to describe sociodemographic and job characteristics, to
classify the profile of accidents, to identify the vaccination history and serological status for
hepatitis B, and to quantify the direct cost of post-exposure management and preventive
measures for hepatitis B. METHODOLOGY: A cross-sectional, descriptive study with a partial
economic evaluation of the cost analysis type, focusing on direct medical costs among health
care workers exposed to biological material in the municipality of Goiania, accidents registered
in the SINAN-NET database in the period 2006-2016. RESULTS: This study included 7,265
recorded accidents with biological material, being predominantly female health care workers
(80.5%), nursing staff (55.2%) with secondary education (43.0%), with accidents involving
blood (74.4%), those being percutaneous (72.4%). The mean age was 34 years, with the age
group 21-30 years being the most predominant. Among those exposed, 85.1% received all
three doses of the vaccine, and of those, 44.6% performed the anti-HBs test at the time of
the accident. The prevalence of HBsAg among known source patients was 1.8% (95% CI 1.0-
3.2). The costs analyzed in this study were the anti-HBs test, HBsAg test, IGHAHB and a
worker health office visit. Considering this history, the direct cost of occupational post-
exposure management for hepatitis B among victims was evaluated in four different scenarios,
and the direct cost ranged from R$ 3,615.52 (Int$ 6.573,67) to R$ 835,751.52
(Int$1.519.548,22). The post-exposure scenarios for HBV that presented the greatest direct
medical cost impact for public health were the scenarios in which the porkers had anti-HBs
<10 IU/ml and were exposed to an HBsAg-positive, unknown source patient. The direct cost
of performing the anti-HBs test after primary vaccination among 7.265 workers was R$
207,415.75 (Int$ 377,119.54). CONCLUSION: The direct per capita cost of post-exposure
management was higher than the direct cost of performing the pre-exposure anti-HBs test,
money that could be invested in policies that protect the health of the worker. / INTRODUÇÃO: A infecção pelo Vírus da Hepatite B (HBV) é um problema mundial de saúde
pública, e o custo do tratamento para hepatite B é elevado. Os acidentes de trabalho com material
biológico entre Trabalhadores da Área da Saúde (TAS) apresentam risco de transmissão desse
vírus. A principal prevenção contra o HBV é a vacinação seguida da realização do teste anti-HBs
após um a dois meses da última dose da vacina, entretanto o exame não é uma rotina pós-vacinação
primária no Sistema Único de Saúde (SUS), no Brasil. OBJETIVOS: Comparar o custo direto
médico, sob a perspectiva do SUS, da avaliação do status sorológico após as três doses da vacina
contra hepatite B ou após vacinação primária para hepatite B com o manejo pós-exposição
ocupacional, relacionado ao vírus da hepatite B entre trabalhadores da área da saúde, vítimas de
acidente com material biológico. Os objetivos específicos: descrever características
sociodemográficas e laborais, identificar o perfil dos acidentes, identificar o histórico vacinal e
status sorológico para hepatite B e quantificar o custo direto do manejo pós-exposição e das
medidas de prevenção para hepatite B. METODOLOGIA: estudo transversal, descritivo e de
avaliação econômica parcial do tipo análise de custo, com enfoque no custo direto médico entre
TAS, vítimas de acidentes com material biológico no município de Goiânia, acidentes registrados
no banco de dados do SINAN-NET, no período de 2006 a 2016. RESULTADOS: foram
registrados 7.265 acidentes com material biológico, sendo, predominantemente, entre TAS do sexo
feminino (80,5%), da equipe de enfermagem (55,2%), com ensino médio (43,0%), acidentes que
envolveram sangue (74,4%) e acidentes percutâneos (72,4%). A média de idade entre os TAS foi
de 34 anos, sendo a faixa etária de 21 a 30 anos a mais predominante. Entre os TAS expostos,
85,1% possuíam as três doses da vacina e desses, 44,6% realizaram o teste anti-HBs no momento
do acidente. A prevalência de HBsAg entre pacientes-fonte conhecidos foi de 1,8% (IC 95% 1,0 –
3,2). Os custos analisados, neste estudo, foram o teste anti-HBs, teste HBsAg, IGHAHB e consulta
médica em saúde do trabalhador. Considerando esse histórico, o custo direto do manejo pós-
exposição ocupacional para hepatite B entre vítimas foi avaliado em quatro diferentes cenários,
nominados A, B, C e D, e o custo direto variou de R$ 3.615,52 (Int$ 6.573,67) a R$ 835.751,52
(Int$ 1.519.548,22). Os cenários de pós-exposição ao HBV que apresentaram maior impacto de
custo direto médico para o SUS foram os cenários em que os TAS possuíam anti-HBs < 10 UI/ml
e foram expostos a paciente-fonte HBsAg positivo e a paciente-fonte desconhecido. O custo direto
da realização do teste anti-HBs após vacinação primária entre 7.265 TAS foi de R$ 207.415,75
(Int$ 377.119,54). CONCLUSÃO: O custo direto per capita do manejo pós-exposição foi mais
elevado do que o custo direto da realização do teste anti-HBs pós-vacinação primária entre TAS,
vítimas de acidente com material biológico, dinheiro que poderia ser investido em políticas para
saúde do trabalhador.
|
103 |
Drogas modificadoras do curso da doença no tratamento da Artrite Reumatoide: sintéticos combinados versus agentes biológicos: revisão sistemática e estudo econômico / Disease modifying anti-rheumatic drug in rheumatoid arthritis : combination of synthetic versus biological agents: systematic review and cost studyHenry Dan Kiyomoto 10 August 2018 (has links)
INTRODUÇÃO: A Artrite Reumatóide (AR) é caracterizada pelo aspecto inflamatório crônico articular e é a doença autoimune mais comum em todo o mundo. A categoria de medicamentos modificadores do curso da doença (MMCD) é dividido em dois grupos, sintéticos e biológicos. Há controversos estudos em relação a comparação entre estas alternativas, principalmente, devido ao elevado custo dos biológicos. O objetivo deste estudo foi realizar uma avaliação econômica do tratamento da AR, comparando a terapia combinada de MMCD sintéticos versus MMCD biológicos, utilizando de dados da literatura e de custo na perspectiva do SUS. MÉTODOS: Foi realizado uma revisão sistemática com metanálise das bases Medline e Embase os ensaios clínicos randomizados(ECR) que fizeram comparação direta entre o uso de MMCD sintéticos versus os MMCD biológicos. A remissão foi considerada para DAS28 < 2,6. Os itens que compõe o custo seguiram a diretrizes do Ministério da Saúde do Brasil e os valores foram recuperados da tabela do Sistema de Informação Ambulatorial do SUS, e do Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS, dados do ano 2016/2017. RESULTADOS: Foram incluídos 6 ECR. No seguimento de até 6 meses o RR=0,70 (IC95% 0,57 a 0,85) a favor dos biológicos. No seguimento entre 12 a 24 meses não houve diferença estatisticamente significante, RR=0,91 (IC95% 0,80 a 1,05). Um ano do tratamento com MMCDs combinado custa R$2445,60 e os Anti-TNF custa R$ 52.821,57. CONCLUSÃO: A remissão da atividade clínica da AR pode ser obtida pelo uso de DMARD sintéticos ou por Agentes Biológicos. Análise de custo-minimização mostrou que uma economia substancial a cada mês evitado de uso dos MMCD biológicos / INTRODUCTION: Rheumatoid arthritis (RA) is the most common autoimmune disease in the world, which leads to a chronic joint inflammation. There are two types of disease-modifying anti-rheumatic drugs (DMARD): synthetical and biological. The comparison between both drugs is controversial, mostly because of the high cost of the biological ones. The aim of this study was to develop an economic evaluation of RA treatments, comparing combined therapy with synthetic DMARD versus biological DMARD, based on literature review and cost analysis on SUS data. METHODS: Systematic review with meta-analysis of randomized clinical trials (RCT) was conducted on Medline and Embase database about direct comparisons of synthetic DMARD and biological DMARD. Remission was set for DAS28 < 2.6. Cost analysis was based on the guidelines of the Brazilian Ministry of Health and cost values were extracted from the SUS\'s Ambulatory Information System table, Management System of Procedures Table, and Medicine and OPM table, for 2016/2017. RESULTS: Six RCT were included. For six months follow-up, RR=0.70 (IC95% 0.57 to 0.85) in favour of biologicals. For 12-24 months follow-up, both DMARD were similar, RR=0.91 (IC95% 0.80 to 1.05). One-year treatment with DMARD costs R$2445,60 e Anti-TNF costs R$ 52.821,57. CONCLUSION: Remission of clinical activity of RA can be reached with synthetic or biologic DMARD. Minimizing-cost analysis showed a monthly expressive saving avoinding the biologic DMARD
|
104 |
Avaliação do custo e da eficácia da implantação de um protocolo de prevenção de úlcera por pressão em uma unidade de pronto socorro adulto / Efficiency and cost assessment for implementation of a pressure ulcer prevention protocol in hospital emergency servicesCleide Maria Caetano Baptista 27 April 2016 (has links)
Introdução: O atendimento nos Serviços de Emergência não está direcionado para a prevenção de agravos, como a ocorrência de úlceras por pressão (UP), visto que é centrado na manutenção da vida e na estabilização das condições hemodinâmicas dos pacientes. Contudo, há evidências de que poucas horas de permanência em leitos de observação são suficientes para o desenvolvimento de UP tornando fundamental a identificação dos pacientes de risco e a adoção precoce de medidas preventivas. Objetivo: Avaliar os custos e a eficácia da implantação de um protocolo de prevenção de UP na Unidade de Pronto Socorro Adulto (PSA) do Hospital Universitário da Universidade de São Paulo (HU-USP). Método: Trata-se de pesquisa quantitativa, exploratório-descritiva, na modalidade de estudo de caso único. Previamente a implantação do protocolo realizou-se o levantamento dos índices de prevalência e de incidência de UP. Em seguida foi desenvolvido um programa educacional teórico-prático, com ênfase na prevenção de UP, destinado à equipe de enfermagem. Três meses após a implementação do protocolo levantou-se, novamente, os índices de prevalência e de incidência de UP. Para a apuração dos custos diretos foram mapeadas as etapas relativas à aquisição de produtos, acessórios e equipamentos e levantamento dos índices de prevalência e incidência de UP antes e depois da implementação do protocolo. O salário hora/profissional foi multiplicado pelo tempo despendido em cada atividade e o custo unitário dos insumos multiplicado pela quantidade adquirida para a viabilização do protocolo. Resultados: Antes da implantação do protocolo de prevenção de UP, foi obtido o índice de prevalência de 6,67% e de incidência de 3%. Os custos diretos da implantação do protocolo totalizaram R$ 31.870,00 (100%) sendo R$ 11.650,93 (36,56%) relativos às atividades de implementação; R$ 10.102,90 (31,70%) referentes à MOD das enfermeiras que levantaram os índices de prevalência e incidência de UP antes da implantação; R$ 7.079,67 (22,21%) referentes à MOD das enfermeiras que levantaram os índices de prevalência e incidência de UP depois da implementação e R$ 3.036,50 (9,53%) para a aquisição de produtos, acessórios e equipamentos. Após a implementação evidenciou-se a diminuição nos índices de prevalência e de incidência para 0% e 1,38%, respectivamente. Conclusão: O investimento na capacitação teórico-prática dos profissionais de enfermagem e a aquisição de produtos, acessórios e equipamentos, necessários para viabilizar a exequibilidade do protocolo de prevenção, são fatores indissociáveis para o alcance de um resultado eficaz e, consequentemente, melhoria contínua da qualidade da assistência. / Introduction: The care in Emergency Services is not directed at the prevention of diseases, as the occurrence of pressure ulcers (PU), since its focus is based on the maintenance of life and stabilization of hemodynamic conditions of patients. However, there is evidence that a few hours spent in observation beds are sufficient for the development of PU, being important to identify risk patients and the early adoption of preventive measures. Objective: To evaluate the cost and effectiveness for the implementation of a PU prevention protocol in Adult Emergency Services (AES) at the University Hospital of the Universidade de São Paulo (UH-USP). Method: This is quantitative, exploratory and descriptive study, with a single case study design. Previously to the protocol implementation, a survey on the prevalence and incidence of PU was carried out. Next, theoretical and practical educational program, with emphasis on prevention of PU, was developed for the nursing staff. Three months after the protocol implementation, again, the prevalence and incidence of PU was assessed. For the calculation of direct costs, the stages related to the acquisition of products, accessories and equipment were mapped, and also a survey on the prevalence and incidence of PU before and after protocol implementation was performed. The hourly wage / professional was multiplied by the time spent on each activity and the unit cost of inputs multiplied by the amount acquired for the viability of the protocol. Results: Before the implementation of PU prevention protocol, the prevalence rate of 6.67% and incidence of 3% were obtained. The direct costs for implementing the protocol amounted to R $ 31.870.00 (100%) being R $ 11.650,93 (36.56%) regarding the implementation of activities; R $ 10.102,90 (31.70%) for the MOD of nurses who raised the prevalence and incidence of UP rate before implementation; R $ 7.079,67 (22.21%) for the MOD of nurses who raised the prevalence and incidence of UP rates after implantation and R $ 3.036,50 (9.53%) for the acquisition of products, accessories and equipment. After implantation it was observed a decrease in prevalence and incidence rates to 0% and 1.38% respectively. Conclusion: Investment in theory and practice training for nurses and the acquisition of products, accessories and equipment necessary to enable the feasibility of the prevention protocol, are factors inextricably linked to achieving an effectively outcome and consequently improving continuous quality of care.
|
105 |
Vauvaperhetyö keskosten äitien tukena:tuen sisällölliset piirteet, kustannukset ja vaikutukset keskosten ensimmäisen elinvuoden hoitokustannuksiinKorhonen, A. (Anne) 12 December 2003 (has links)
Abstract
The purpose of this study was to evaluate characteristics, the cost of the intervention and effects of participation on the first year preterm cost of care.
Home-based intervention is a new preventive nursing intervention, which focuses mainly on early interaction between an infant and its mother. Many long-term advantages have been found in developmental issues of preterm infants, on mothers caring skills and the mother-child relationship. Even though those positive effects are well known, there still remains a gap of information concerning effective characteristics of the intervention as well as costs of such an intervention.
The study focused on two main questions: 1) What are the characteristics of the intervention perceived by the mothers with preterm infants? 2) What are the costs of the intervention and what kind of effects did the intervention have on the first year cost of care of preterm infants?
This was a retrospective evaluation study. The population consisted of preterm infants (≤ 32 gw), who were treated in eastern an northern Finland during 1996?1998. All infants received usual preterm care. In addition to this, the intervention group participated in the intervention. Data was gathered during 1998?1999. Two groups of mothers were interviewed. The first were mothers (N = 17), who described the care for a preterm infant at home. The other group of mothers (N = 7) evaluated the intervention. Content analysis was performed inductively and deductively. The last one was based on concept and characteristics of social support.
Cost of the intervention was evaluated as salary, time and travelling cost for the nurse. Costs of preterm care were computed as direct and indirect social and family costs and compared the first year cost of intervention (N = 18) and control (N = 118) group of preterm infants. Data was gathered by a questionnaire and from hospital statistics and patient files. Descriptive statistical methods as well comparing the means were used.
The results indicated an exceptional motherhood of the mothers with preterm infants. The exceptionality consisted of challenges of care for the infant, needs for information related to prematurity and care for the infant. Many fears, worries and feelings of guilt burden the mothers. The home-based intervention supported the mothers of the intervention group by equipping them with situation suitable information concerning prematurity and giving them emotional, integrative and active support.
The mean cost of the intervention was 970 euroa per an infant to the hospital. Costs of new episodes of care and primary health care were smaller among the intervention group than among the control group. Cost-analysis indicated that the initial phase of care formed the main proportion of infants' first year cost of care.
The results suggest that the home-based intervention may have potential to support mothers with preterm infant without significantly increasing the cost of care. / Tiivistelmä
Tämän tutkimuksen tarkoituksena oli kuvailla vauvaperhetyön sisältöä, arvioida vauvaperhetyön tuottamisesta aiheutuvia kustannuksia sairaalalle sekä vertailla siihen osallistumisen vaikutuksia keskosten ensimmäisen elinvuoden hoitokustannuksiin.
Vauvaperhetyöllä on havaittu olevan vuosia kestäviä suotuisia vaikutuksia keskosten kehitykseen, äidin hoivataitoihin ja vuorovaikutukseen. Kuitenkaan ei ole tietoa siitä, millaisena tuen vastaanottajat sen näkevät. Samoin on niukasti tietoa siitä, paljonko vauvaperhetyön tuottaminen maksaa.
Tutkimustehtävinä olivat: Millaisena tukena vauvaperhetyö ilmeni keskosten äideille? Millaiset olivat vauvaperhetyön kustannukset sairaalalle ja miten siihen osallistuminen vaikutti keskosten ensimmäisen elinvuoden hoitokustannuksiin? Tutkimus toteutettiin retrospektiivisena arviointitutkimuksena. Tutkimusjoukko koostui vuosina 1996?1998 Itä- ja Pohjois-Suomen alueilla hoidetuista keskosista (≤ 32 vk). Kaikille keskosille annettiin tavanomainen hoito, jonka lisäksi interventioryhmän keskoset osallistuivat vauvaperhetyöhön. Aineistot koottiin vuosina 1998?1999. Vauvaperhetyön sisällöllisistä piirteistä koottiin tietoa kahden äitiryhmän teemahaastattelulla. Ensimmäisen aineiston äidit (N = 17) kuvailivat keskosten hoitoa kotona. Toisen aineiston äidit (N = 7) kuvailivat vauvaperhetyön sisältöä. Haastatteluaineistot analysoitiin aineisto- ja teorialähtöisellä sisällönanalyysilla. Jälkimmäisen luokittelurunko rakentui sosiaalisen tuen ominaispiirteiden mukaan.
Vauvaperhetyön kustannusten arviointi perustui perhetyöntekijän palkkaan sekä kotikäyntien matka- ja aikakustannuksiin. Interventioon osallistumisen vaikutuksia hoitokustannuksiin arvioitiin vertailemalla interventio- (N = 18) ja verrokkiryhmän (N = 118) keskosten hoitokustannuksia. Tietoa koottiin vanhemmille suunnatulla kyselylomakkeella, sairaalan tiedostoista, potilasasiakirjoista ja perhetyöntekijän tiedostoista. Kustannukset laskettiin suorina ja epäsuorina yhteiskunnalle ja perheille aiheutuneina kustannuksina. Tulokset analysoitiin taulukkolaskennalla käyttäen kuvailevan tilastotieteen menetelmiä ja keskiarvotestejä.
Aineistolähtöisen sisällönanalyysin mukaan keskosen äitiys oli erilaista äitiyttä, jota määritti keskosten hoidon asettamat vaatimukset ja äitien emootiot. Hoidon vaatimuksissa korostuivat päivittäisen hoidon, tiedon tarpeen ja erilaisen arjen asettamat tiedolliset ja taidolliset haasteet. äitien emootiot sisälsivät keskosten terveydentilaan ja kehitykseen sekä äitiin itseensä liittyviä pelkoja, huolia ja syyllisyyden tunteita. Teorialähtöisen analyysin perusteella vauvaperhetyön keskeinen sisältö muodostui tilannekohtaisen, keskosten hoitoon sovelletun erityistiedon antamisesta sekä perhetyöntekijän saavutettavuudesta. Muita vauvaperhetyön antaman tuen muotoja olivat emotionaalinen, integroiva ja aktiivinen tuki.
Vauvaperhetyön tuottaminen maksoi sairaalle keskimäärin 970 euroa lasta kohden. Vauvaperhetyöhön osallistuneiden interventioryhmän keskosten uusien hoitojaksojen ja perusterveydenhuollon kustannukset olivat verrokkien kustannuksia matalammat. Tulokset viittaavat siihen, että vauvaperhetyöllä voidaan vastata keskosten äitien tuen tarpeisiin lisäämättä merkittävästi hoitokustannuksia.
|
106 |
Suomalaisen aikuisen astma – kysely- ja rekisteritutkimus vuonna 2000Ikäheimo, P. (Pekka) 06 May 2008 (has links)
Abstract
The aim of this doctoral thesis is to provide an overall description of Finnish adult asthma patients in the year 2000, including their symptoms, treatment and the resulting costs. The implementation of treatment was evaluated from the perspective adopted in the National Asthma Programme 1994–2004.
The research was based on questionnaire data acquired from a sample extracted from the Finnish Social Insurance Institution's asthma register, with which existing register data were combined, so that the eventual series comprised patients suffering from asthma and possibly other chronic obstructive pulmonary diseases.
The majority of the asthma patients were women of working age. Smoking was most common among young adults (43% of the men and 35% of the women), while the number who had stopped smoking increased towards the older age groups among the men but remained constant among the women. The older age groups also had more serious asthma, more frequent cases of other chronic pulmonary and somatic illnesses, more problems in coping with everyday life and greater treatment needs than the younger patients. Early retirement for health reasons was common. More than half of the women and one in five of the men aged 65 years or over were living alone.
The patients who suffered from asthma alone normally managed relatively well. Their symptoms could be kept under control with anti-inflammatory medication at a moderate overall cost, but concurrent obstructive pulmonary disease almost tripled the direct cost of asthma treatment and increased hospital costs practically five-fold. Smoking led to further expense in the case of those with asthma and obstructive pulmonary disease combined.
The transfer of responsibility for asthma treatment from specialized care to the basic health care system would appear in general to be justified. Smoking and its associated chronic obstructive pulmonary diseases present a particular challenge for the management of asthma. / Tiivistelmä
Tässä väitöskirjatyössä tutkittiin suomalaisen aikuisen astmapotilaan kokonaiskuva ja selvitettiin hänen oireiluaan, hoitoaan ja tästä aiheutuvia kustannuksia vuonna 2000. Astman hoidon toteutumista arvioitiin Valtakunnallinen astmaohjelma 1994–2004:n näkökulmasta.
Tutkimuksessa käytettiin Kelan astmarekisteristä valtakunnallisesti poimitun potilasotoksen kyselyaineistoa rekisteritietoja siihen yhdistäen. Lopullisen tutkimusaineiston muodostivat astmaa ja sen lisäksi mahdollisesti muita pitkäaikaisia ahtauttavia keuhkosairauksia sairastavat potilaat.
Enemmistö astmapotilaista oli naisia ja työikäisiä. Tupakointi oli yleisintä nuorilla aikuisilla miehillä (43 %) ja naisilla (35 %). Tupakoinnin lopettaneiden osuus suureni miehillä vanhempiin ikäryhmiin mentäessä, kun taas naisilla osuus pysyi samansuuruisena. Vanhemmissa ikäryhmissä astma oli vaikeampaa ja muu keuhko- ja somaattinen pitkäaikaissairastavuus, toimintakyvyn ongelmaisuus ja hoidon tarve nuorempia runsaampaa. Ennenaikainen eläköityminen oli yleistä. Kuusikymmentäviisi vuotta täyttäneistä ja sitä vanhemmista naisista useampi kuin joka toinen ja miehistä joka viides asui yksin.
Pelkkää astmaa sairastava voi yleisesti arvioiden hyvin. Hänen oireilunsa oli hallittavissa anti-inflammatorisella lääkityksellä kohtalaisen vähäisin kokonaishoidon kustannuksin. Samanaikainen keuhkoahtaumatauti lähes kolminkertaisti astman hoidosta aiheutuneet suorat kustannukset ja lähes viisinkertaisti sairaalahoidosta aiheutuneet kustannukset. Astmaa ja keuhkoahtaumatautia sairastavilla tupakointi lisäsi edelleen kustannuksia.
Astmapotilaan kokonaisuuden näkökulmasta hoidon päävastuun siirto erikoissairaanhoidosta perusterveydenhuoltoon vaikuttaa tarkoituksenmukaiselta. Tupakointi ja siihen liittyvät muut pitkäaikaiset ahtauttavat keuhkosairaudet muodostavat erityisen haasteen astman hoitojärjestelmälle.
|
107 |
Estudos para avaliação de custo-efetividade do tratamento do transtorno de déficit de atenção/hiperatividade com metilfenidato de liberação imediata no BrasilMaia, Carlos Renato Moreira January 2014 (has links)
Introdução O Transtorno de Déficit de Atenção/hiperatividade (TDAH) tem sido muito estudado, mas informações econômicas referentes ao seu tratamento com o metilfenidato de liberação imediata (MFD-LI) ainda necessitam ser exploradas. Grande parte da população mundial, principalmente aqueles que vivem em países em desenvolvimento, utiliza essa formulação como principal escolha para o tratamento do TDAH. Esses países, por sua condição financeira, necessitam informações de análises econômicas para administrar de forma eficiente os recursos públicos destinados aos setores da saúde. Objetivos Avaliar a eficácia do MFD-LI através de estudos com tempo superior a 12 semanas, e realizar uma análise econômica para o tratamento do TDAH com MFD-LI para crianças e adolescentes brasileiros. Método O estudo foi planejado em cinco etapas: 1) estimativa de custo do não tratamento do TDAH para o Brasil, e estimativa de economia com tratamento com MFD-LI; 2) revisão sistemática da literatura nas principais bases de dados internacionais onde se buscaram estudos abertos com tratamento do TDAH com MFD-LI por tempo igual ou superior a 12 semanas; também foram feitas metanálises e uma metaregressão 3) estudo naturalístico para obterem-se dados de uma amostra brasileira referentes a probabilidades de uso e sucesso com tratamento com MFD-LI por 12 semanas, e estimar os utilities desses indivíduos; 4) painel Delphi com especialistas em TDAH no Brasil; 5) estudo de custo-efetividade para o tratamento do TDAH com MFD-LI no Brasil, utilizando um Modelo de Markov. A perspectiva adotada será a do sistema público de saúde brasileiro como pagador. Resultados Os resultados principais encontrados para cada uma das etapas foram: 1) a estimativa de custos anuais com o TDAH não tratado no Brasil foi de R$ 1.594 bilhões/ano, e da quantia que poderia ser economizada se tratado, R$ 1 bilhão/ano. 2) na revisão sistemática da literatura, de 4.498 resumos, sete foram incluídos para compor a metanálise. O tempo de tratamento variou entre 13 e 104 semanas. O efeito agregado para desatenção e hiperatividade medida pelos pais, respectivamente, foi 0.96 (95%CI 0.60 - 1.32) e 1.12 (95%CI 0.85 - 1.39), e pelos professores 0.98 (95%CI 0.09 - 1.86) e 1.25 (95% CI 0.7 - 1.81). A metaregressão não mostrou associação entre as variáveis idade, qualidade do artigo e tempo de tratamento com heterogeneidade. 3) no estudo naturalístico, de 171 pacientes avaliados, 73 forneceram informações para o baseline, e 56 para a 12a semana de tratamento com MFD-LI. Os utilities para um paciente com TDAH não tratado (baseline) foram 0.69 (crianças) e 0.66 (adolescentes), e estimaram-se ganhos entre 0.09 a 0.10 utilities/mês, se tratados adequadamente. 4) no painel Delphi, de 26 especialistas, 14 responderam o questionário online, e foi estimado que a probabilidade dos pacientes não tratados se manterem sintomáticos na 12a semana seria de 91%, e 9% a probabilidade de melhora espontânea; 5) no estudo de custo-efetividade, para o caso base, estimou-se que o Incremental Cost Effectiveness Ratio (ICER) seja I$9,103/QALY (Quality Adjusted Life Years) para crianças e I$11,883/QALY para adolescentes em um horizonte temporal de 06 anos. Para os cenários mais desfavoráveis, os ICERS mais elevados foram I$95,164/QALY para 50% de sucesso com o tratamento, e I$15,000/QALY para 70% de adesão em um horizonte temporal de 06 anos. Conclusões O MFD-LI é um tratamento eficaz para crianças e adolescentes, por um período superior a 12 semanas. Entretanto, o Brasil pode estar aumentando os custos referentes à saúde por não estar fornecendo um tratamento eficaz e economicamente acessível para o TDAH. O tratamento mostrou ser uma opção custo-efetiva para crianças e adolescentes brasileiros, mesmo em cenários desfavoráveis para o tratamento. / Introduction Attention-Deficit/Hyperactivity Disorder (ADHD) is a well-known psychiatric disorder, but some economical aspects of the treatment with Methylphenidate Immediate-release (MPH -IR) still need to be explored. A large number of people around the world, most living in Low-Middle Income Countries (LMIC), use this formulation as the first choice for ADHD treatment. These countries, due to their financial condition, need information from health economic analyzes to efficiently manage the public resources allocated to the health sector. Objective To study the efficacy of MPH-IR reviewing studies conducted for more than 12 weeks long, and to perform an economic analysis for the treatment of ADHD with MPH-IR for Brazilian children. Method The study was planned in a five stages process: 1) to estimate the cost of untreated ADHD for Brazil, and to estimate the savings if MPH-IR were adequately provided; 2) systematic review of the literature to identify papers published where young patients with ADHD were treated with MPH-IR for more than 12 weeks, and to perform a meta-analysis and a meta-regression; 3) to conduct a naturalistic study with a Brazilian sample to collect the probabilities of use and success with the MPH-IR treatment for 12 weeks, and to estimate the utilities; 4) to perform a Delphi panel with ADHD Brazilian experts; 5) to conduct a cost-effectiveness analysis for the treatment of ADHD with MPH-IR in Brazil, using a Markov model. The perspective is the one of the Brazilian public health system as the payer. Results The main findings for each step were: 1) the estimated annual expenditures with untreated ADHD in Brazil were R$1.594billon/year, and the estimated amount that could be saved was R$1billion/year; 2) in the systematic review, from 4,498 abstracts, 7 studies were selected. The length of treatment ranged from 13 to 104 weeks. The aggregate effects for inattention and hyperactivity, according to parents evaluations were respectively 0.96 (95%CI 0.60 - 1.32) and 1.12 (95%CI 0.85 - 1.39), and for teachers 0.98 (95%CI 0.09 - 1.86) e 1.25 (95% CI 0.7 - 1.81). There was no evidence of association between heterogeneity and the variables, age, paper quality and length of treatment; 3) in the naturalistic study, from 171 patients assessed, 73 provided information in the baseline, and 56 in the 12th week of MPH-IR treatment. Utilities for an untreated ADHD patient (baseline) were 0.69 (children) and 0.66 (adolescents), and it was estimated a gain ranging from 0.09 to 0.10 utilities/month if subjects were properly treated; 4) in the Delphi Panel, 26 experts were addressed and 14 filled in the online questionnaire. It was estimated the probability of untreated patients to remain symptomatic on the 12th week to be 91%, and the probability of spontaneous improvement, 9%; 5) in the cost-effectiveness analysis, for the base case, it was estimated an Incremental Cost Effectiveness Ratio (ICER) of I$9,103/QALY (Quality Adjusted Life Years) for children and I$11,883/QALY for adolescents, in a time horizon of 6 years. The worst case scenarios were also tested, and the highest ICER were I$95,164/QALY when patient reached 50 % of success with the treatment, and I$15,000/QALY if only 70% of use was observed in a time horizon of 6 years. Conclusions MPH-IR is an efficacious treatment for ADHD children and adolescents for periods longer than 12 weeks. However, Brazil may be probably wasting money due to not provide an efficient and affordable treatment for ADHD such as the MPH-IR. The treatment proved to be cost-effective for children and adolescents living in Brazil, even when the worst case scenarios were tested.
|
108 |
Komplementäre Therapie der zervikalen DystonieViehmann, Manuel Alexander 14 June 2013 (has links) (PDF)
In der Behandlung der zervikalen Dystonie wird die Therapie mit Botulinumtoxin (BTX) erfolgreich angewendet. Neben dieser Therapie werden von Patienten oft alternative Therapien (CAM [Complementary and Alternative Medicine]) angesprochen und ausprobiert. Diese Studie geht der Frage nach, wie häufig CAM-Therapien genutzt werden, wie deren Wirkung bewertet wird und ob es Prädiktoren für die Therapiewahl gibt. Zur Datenerhebung wurden 265 Fragebögen von zwei Patientengruppen ausgewertet. Gruppe 1 (n=101) bestand aus Patienten der Botulinumtoxinsprechstunde des Universitätsklinikums Leipzig und der Paracelsus Klinik Zwickau. Gruppe 2 (n=165) wurde aus Mitgliedern des Selbsthilfeverbandes Bundesverband-Torticollis e.V. rekrutiert. Bei 86% der Patienten wurde die Therapie mit BTX angewendet. Von den Therapiemöglichkeiten der CAM wurden am häufigsten physikalische Therapien (Massagen n=171) genannt. Am besten bewertet wurden jedoch, neben der BTX-Therapie, spezielle physiotherapeutische sowie psychotherapeutische Verfahren. Die CAM-Therapien wurden häufig in Kombination mit der BTX-Therapie angewendet und von Patienten, deren Erkrankung einen langen chronischen Verlauf vorwies (>10 Jahre). Als Prädiktoren für die Wahl einer CAM-Therapie zeigten sich eine Zugehörigkeit zur Gruppe 2, aufgetretene Nebenwirkungen im Rahmen der BTX-Therapie, männliches Geschlecht und erhöhter Stress bei den Erkrankten. Außerdem fand sich ein signifikanter Unterschied zu einem höheren Bildungsabschnitt und Arbeit in gehobeneren Berufsgruppen bei Patienten, die vermehrt CAM Therapie anwenden. Zusammenfassend wurden CAM-Therapien, neben der Behandlung mit BTX, häufig von den Befragten angewendet. Hohe Zufriedenheitswerte erzielte eine Kombination mit physiotherapeutischen Verfahren oder Psychotherapie. Die Wahl von CAM-Therapien ist von der Erkrankungsdauer, Bildungslage und finanziellen Ressourcen abhängig.
|
109 |
Durée de lʼexposition avec symptômes, séquelles et coûts de lʼasthme professionnel en relation avec le statut psychologique et socioéconomiqueMiedinger, David 04 1900 (has links)
Le facteur le plus important de pronostic de l'asthme professionnel (AP) est la durée des symptômes avant le retrait de lʼexposition à lʼagent causant lʼAP. La qualité de vie réduite, la détresse psychologique et les maladies psychiatriques sont des conditions souvent associées à l'AP. Notre objectif était d'identifier les facteurs, incluant le statut socioéconomique, qui ont une influence sur lʼintervalle de temps nécessaire pour présenter une requête à une agence médicolégale à la suite de lʼapparition de symptômes dʼasthme et de confirmer qu'un tel délai est associé à un moins bon pronostic respiratoire et à des coûts directs plus élevés. En outre, nous avons examiné la relation entre les variables cliniques et socio-économiques dʼune part et leur influence sur les facteurs psychologiques et économiques dʼautre part chez des travailleurs atteints d'AP. Ensuite, nous avons voulu évaluer si les individus souffrant de détresse psychologique (DP) et de morbidité psychiatrique pourraient être identifiés en utilisant un instrument mesurant la qualité de vie (QV). Lʼétude a été effectuée auprès dʼindividus ayant déposé des demandes d'indemnisation pourʼAP auprès du Commission de la sécurité et de la santé du travail du Québec (CSST). Les données ont été recueillies au moment de la réévaluation, soit environ deux ans et demi après le diagnostic. Outre la collecte des marqueurs cliniques de l'asthme, les individus ont été soumis à une évaluation générale de leur histoire sociodémographique et médicale, à une brève entrevue psychiatrique (évaluation des soins primaires des troubles mentaux, PRIME-MD) et à un ensemble de questionnaires, incluant le Questionnaire sur la qualité de vie - AQLQ(S), le Questionnaire respiratoire de St. George (SGRQ) et le Psychiatric Symptom Index (PSI).Soixante personnes ont été incluses dans l'étude. Etre plus âgé, avoir un revenu supérieur à 30 000$ CA etêtre atteint dʼAP dû à un allergène de haut poids moléculaire ont une association positive avec le nombre dʼannées dʼexposition avec symptômes avant le retrait. Au cours de la période de suivi, le nombre dʼannées dʼexposition avec symptômes était plus grand chez les individus ayant une hyperréactivité bronchique persistante. Par ailleurs, la présence de symptômes au poste de travail pendant moins d'un an est associée à une réduction des coûts directs. Les paramètres de QV et de DP avaient des corrélations modérées avec les marqueurs cliniques de lʼAP. Les plus fortes associations avec ces variables ont pu être observées dans les cas de la sévérité de l'asthme, des statuts dʼemploi et matrimonial, du revenu et de la durée de la période de travail avec l'employeur. Un seuil de 5,1 au niveau de la sous-échelle de la fonction émotionnelle de lʼAQLQ(S) sʼest avéré avoir la meilleure valeur discriminante pour distinguer les individus avec ou sans détresse psychiatrique cliniquement significative selon le PSI. Nous avons été en mesure d'identifier les variables socio-économiques associées à un intervalle plus long dʼexposition professionnelle en présence de symptômes dʼasthme. De même, une plus longue période d'exposition a été associée à un moins bon pronostic de la maladie et à des coûts de compensation plus élevés. Ces résultats s'avèrent utiles pour la surveillance de lʼAP qui pourrait cibler ces sous-groupes d'individus. La QV et la PS sont fréquemment réduites chez les individus atteints d'AP qui perçoivent une compensation. Elles sont associées à des marqueurs cliniques de lʼasthme et à des facteurs socio-économiques. En outre, nos résultats suggèrent que le questionnaire de lʼAQLQ(S) peut être utilisé pour identifier les individus avec un niveau de détresse psychologique potentiellement significatif. / The most important factor in the prognosis of occupational asthma (OA) is the length of exposure with symptoms prior to removal from exposure. Impaired quality of life, psychological distress and psychiatric disease are conditions frequently associated with OA. Our goal was to identify factors, including socio-economic status, that can influence the delay in submitting a claim to a medicolegal agency after the onset of asthmatic symptoms, and to confirm that such a delay is associated with a worse respiratory prognosis and higher direct costs. Further, we examined the association between clinical and socio-economic variables and their influence on psychological and cost outcomes in individuals with OA. Next, we wanted to evaluate whether individuals with clinically significant psychological distress (PD) and psychiatric morbidity could be identified by using a quality of life (QOL) measurement instrument. This is a study of individuals who filed claims for compensation for occupational asthma from the Workersʼ Compensation Board of Quebec (the CSST). Data were collected at re-evaluation, approximately two and a half years after diagnosis. Besides collecting clinical markers of asthma, individuals underwent a general socio-demographic and medical history evaluation, a brief psychiatric interview (Primary Care Evaluation of Mental Disorders, PRIME-MD) and completed a battery of questionnaires, including the Asthma Quality of Life Questionnaire - AQLQ(S), the St. Georgeʼs Respiratory Questionnaire (SGRQ), and the Psychiatric Symptoms Index (PSI). Sixty individuals were included in the study. Being older, having a revenue of >$30,000 Can. (CAD$) and having OA due to high- molecular- weight agents were all positively associated with the number of years of exposure with symptoms before removal from exposure. Individuals with persistent airway hyperresponsiveness at follow-up had a higher number of years with symptoms. Experiencing symptoms in the workplace for less than one year generated lower direct costs. QOL and PD parameters had moderate correlations with clinical markers of OA. Asthma severity, employment and marital status, income and length of employment with the employer showed the strongest associations with QOL and PD. More impaired QOL was associated with higher direct costs for compensation. A cut-off of 5.1 on the AQLQ(S) emotional function subscale had the best discriminative value to distinguish individuals with or without clinically significant psychological distress according to the PSI. We were able to identify socio-economic variables that were associated with a longer interval during which individuals remained symptomatic in the workplace before being removed from exposure. This longer exposure time was associated with worse disease outcomes and higher compensation costs. These findings could prove to be useful in surveillance programs that could be preferentially targeted for these subgroups of individuals. Impaired QOL and PD are frequent among individuals with OA receiving compensation and are associated with clinical markers of OA and socio-economic factors. Further, our findings suggest that the AQLQ(S) questionnaire could be used to identify individuals with potentially clinically significant levels of psychological distress.
|
110 |
Durée de lʼexposition avec symptômes, séquelles et coûts de lʼasthme professionnel en relation avec le statut psychologique et socioéconomiqueMiedinger, David 04 1900 (has links)
Le facteur le plus important de pronostic de l'asthme professionnel (AP) est la durée des symptômes avant le retrait de lʼexposition à lʼagent causant lʼAP. La qualité de vie réduite, la détresse psychologique et les maladies psychiatriques sont des conditions souvent associées à l'AP. Notre objectif était d'identifier les facteurs, incluant le statut socioéconomique, qui ont une influence sur lʼintervalle de temps nécessaire pour présenter une requête à une agence médicolégale à la suite de lʼapparition de symptômes dʼasthme et de confirmer qu'un tel délai est associé à un moins bon pronostic respiratoire et à des coûts directs plus élevés. En outre, nous avons examiné la relation entre les variables cliniques et socio-économiques dʼune part et leur influence sur les facteurs psychologiques et économiques dʼautre part chez des travailleurs atteints d'AP. Ensuite, nous avons voulu évaluer si les individus souffrant de détresse psychologique (DP) et de morbidité psychiatrique pourraient être identifiés en utilisant un instrument mesurant la qualité de vie (QV). Lʼétude a été effectuée auprès dʼindividus ayant déposé des demandes d'indemnisation pourʼAP auprès du Commission de la sécurité et de la santé du travail du Québec (CSST). Les données ont été recueillies au moment de la réévaluation, soit environ deux ans et demi après le diagnostic. Outre la collecte des marqueurs cliniques de l'asthme, les individus ont été soumis à une évaluation générale de leur histoire sociodémographique et médicale, à une brève entrevue psychiatrique (évaluation des soins primaires des troubles mentaux, PRIME-MD) et à un ensemble de questionnaires, incluant le Questionnaire sur la qualité de vie - AQLQ(S), le Questionnaire respiratoire de St. George (SGRQ) et le Psychiatric Symptom Index (PSI).Soixante personnes ont été incluses dans l'étude. Etre plus âgé, avoir un revenu supérieur à 30 000$ CA etêtre atteint dʼAP dû à un allergène de haut poids moléculaire ont une association positive avec le nombre dʼannées dʼexposition avec symptômes avant le retrait. Au cours de la période de suivi, le nombre dʼannées dʼexposition avec symptômes était plus grand chez les individus ayant une hyperréactivité bronchique persistante. Par ailleurs, la présence de symptômes au poste de travail pendant moins d'un an est associée à une réduction des coûts directs. Les paramètres de QV et de DP avaient des corrélations modérées avec les marqueurs cliniques de lʼAP. Les plus fortes associations avec ces variables ont pu être observées dans les cas de la sévérité de l'asthme, des statuts dʼemploi et matrimonial, du revenu et de la durée de la période de travail avec l'employeur. Un seuil de 5,1 au niveau de la sous-échelle de la fonction émotionnelle de lʼAQLQ(S) sʼest avéré avoir la meilleure valeur discriminante pour distinguer les individus avec ou sans détresse psychiatrique cliniquement significative selon le PSI. Nous avons été en mesure d'identifier les variables socio-économiques associées à un intervalle plus long dʼexposition professionnelle en présence de symptômes dʼasthme. De même, une plus longue période d'exposition a été associée à un moins bon pronostic de la maladie et à des coûts de compensation plus élevés. Ces résultats s'avèrent utiles pour la surveillance de lʼAP qui pourrait cibler ces sous-groupes d'individus. La QV et la PS sont fréquemment réduites chez les individus atteints d'AP qui perçoivent une compensation. Elles sont associées à des marqueurs cliniques de lʼasthme et à des facteurs socio-économiques. En outre, nos résultats suggèrent que le questionnaire de lʼAQLQ(S) peut être utilisé pour identifier les individus avec un niveau de détresse psychologique potentiellement significatif. / The most important factor in the prognosis of occupational asthma (OA) is the length of exposure with symptoms prior to removal from exposure. Impaired quality of life, psychological distress and psychiatric disease are conditions frequently associated with OA. Our goal was to identify factors, including socio-economic status, that can influence the delay in submitting a claim to a medicolegal agency after the onset of asthmatic symptoms, and to confirm that such a delay is associated with a worse respiratory prognosis and higher direct costs. Further, we examined the association between clinical and socio-economic variables and their influence on psychological and cost outcomes in individuals with OA. Next, we wanted to evaluate whether individuals with clinically significant psychological distress (PD) and psychiatric morbidity could be identified by using a quality of life (QOL) measurement instrument. This is a study of individuals who filed claims for compensation for occupational asthma from the Workersʼ Compensation Board of Quebec (the CSST). Data were collected at re-evaluation, approximately two and a half years after diagnosis. Besides collecting clinical markers of asthma, individuals underwent a general socio-demographic and medical history evaluation, a brief psychiatric interview (Primary Care Evaluation of Mental Disorders, PRIME-MD) and completed a battery of questionnaires, including the Asthma Quality of Life Questionnaire - AQLQ(S), the St. Georgeʼs Respiratory Questionnaire (SGRQ), and the Psychiatric Symptoms Index (PSI). Sixty individuals were included in the study. Being older, having a revenue of >$30,000 Can. (CAD$) and having OA due to high- molecular- weight agents were all positively associated with the number of years of exposure with symptoms before removal from exposure. Individuals with persistent airway hyperresponsiveness at follow-up had a higher number of years with symptoms. Experiencing symptoms in the workplace for less than one year generated lower direct costs. QOL and PD parameters had moderate correlations with clinical markers of OA. Asthma severity, employment and marital status, income and length of employment with the employer showed the strongest associations with QOL and PD. More impaired QOL was associated with higher direct costs for compensation. A cut-off of 5.1 on the AQLQ(S) emotional function subscale had the best discriminative value to distinguish individuals with or without clinically significant psychological distress according to the PSI. We were able to identify socio-economic variables that were associated with a longer interval during which individuals remained symptomatic in the workplace before being removed from exposure. This longer exposure time was associated with worse disease outcomes and higher compensation costs. These findings could prove to be useful in surveillance programs that could be preferentially targeted for these subgroups of individuals. Impaired QOL and PD are frequent among individuals with OA receiving compensation and are associated with clinical markers of OA and socio-economic factors. Further, our findings suggest that the AQLQ(S) questionnaire could be used to identify individuals with potentially clinically significant levels of psychological distress.
|
Page generated in 0.081 seconds